The scale of the biopharmaceutical market continues to expand, and the demand for related equipment continues to grow

In recent years, biopharmaceutical technology has developed vigorously and the market space has continued to expand
.
According to Frost & Sullivan’s prediction, the scale of China’s biopharmaceutical market will rapidly expand at an average compound annual growth rate of 18% in the next few years, and reach 59 billion yuan in 2030
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) Relevant industry insiders believe that with the rapid rise of China's biomedical industry, the demand for medical equipment will continue to expand
.
Especially with the introduction of a series of national policies, domestic pharmaceutical companies are transforming from a "generic drug strategy" to an "innovative drug strategy".
Under the background of the emergence of some pharmaceutical companies focusing on the research and development of new drugs in China, biomedical equipment will become more and more important.
The more important the future, the future market prospects for related equipment will become more and more broad
.
It is understood that Chutian Technology released its third quarterly report a few days ago, showing that its revenue in the field of biopharmaceutical equipment has increased significantly
.
Specifically, the announcement shows that the company achieved operating income of 3.
682 billion yuan in the first three quarters, a year-on-year increase of 67.
24%; realized net profit attributable to shareholders of listed companies of 401 million yuan, a year-on-year increase of 723.
53%, and net profit reached the net profit of the previous year.
Twice
.
Among them, Chutian Technology made it clear that new orders increased by 98% compared with the same period last year, and the company increased production, delivery and debugging efforts, which resulted in a substantial increase in revenue and operating costs compared with the same period last year
.
In fact, from the first three quarters, Chutian Technology’s revenue and orders from the biopharmaceutical equipment sector accounted for about 40% of the company’s share, which is enough to explain the strong demand for biopharmaceutical equipment
.
It is understood that in order to further meet the demand for biopharmaceutical equipment in the market, in a survey in September, Chutian Technology also revealed the company's plan for biopharmaceutical-related fields, and will take heavy investment, large-scale development, and planning for biopharmaceutical-related products.
The annual sales growth rate of biopharmaceutical-related process technology and process equipment exceeds that of other product lines
.
At the same time, the company will also benchmark Sartorius in the biological field to complement related product series and industrial chains
.
Coincidentally, Canaan Technology also plans to focus on the development of pharmaceutical liquid dispensing systems, intelligent logistics systems and pharmaceutical R&D service areas for bio-innovative drugs. .
Canaan Technology believes that the rapid development of the biopharmaceutical industry will bring more business opportunities to the company
.
From an overall point of view, the pharmaceutical equipment giants are all entering the field of biopharmaceuticals
.
Some domestic pharmaceutical equipment companies have already begun to conduct various tests on biopharmaceutical production equipment, and strive to obtain a better test result in terms of equipment stability and safety to meet market needs
.
For example, some companies have been committed to promoting the continuous production and intelligent manufacturing of biopharmaceuticals.
At present, their innovatively developed key biopharmaceutical equipment (bioreactors, bioengineering liquid preparation modules) and intelligent production platforms (Bio-PAS) Has been able to greatly improve the efficiency and safety of production
.
However, for a long time, China’s biopharmaceutical equipment industry has had a serious lack of high-end market, the industry’s overall innovation capability is still weak, product quality is uneven, pharmaceutical companies have low trust in domestic biopharmaceutical equipment, and many companies have It is more dependent on issues such as imported equipment
.
For example, the head of a domestic biopharmaceutical company previously stated in an interview with the media that 95% of the company's biopharmaceutical equipment is imported
.
Therefore, in this context, the industry believes that while domestic pharmaceutical equipment companies see opportunities, they also need to continuously increase R&D investment to accelerate the breaking of import monopoly, realize the substitution of imported products, and help China's biopharmaceutical industry to become more Good development
.